Lung Cancer

Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.

Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.

Considerations for optimizing the use of molecular testing in advanced non–small cell lung cancer, addressing insufficient tissue collection and liquid biopsy approaches.

The hallmarks of lung cancer diagnosis and treatment are evolving, evidenced by increases in minimally invasive surgery, and immunotherapy combinations, as well as targeted therapies for rare molecular subsets.

Expert Ticiana Leal, MD, shares her perspective on routine molecular testing practices in advanced non–small cell lung cancer.

Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice.

Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Mark Awad, MD, PhD, discusses how the approval of nivolumab opens the door for the new regimen to become a backbone for future treatment strategies.

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Frank Weinberg, MD, PhD, discusses the treatment options in non–small cell lung cancer harboring NTRK fusions.

Closing out her discussion on the management of actionable mutations in NSCLC, Meghan Mooradian, MD, highlights the detection and implications of KRAS/TP53 mutations.

Consolidation therapy with durvalumab and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer.

Lung cancer remains the most common cause of cancer death in the United States.

Chao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion supporting the approval of adjuvant atezolizumab, after complete resection and platinum-based chemotherapy, in adult patients with non–small cell lung cancer with a high risk of recurrence and whose tumors express PD-L1 of 50% or higher and do not harbor EGFR mutations or ALK alterations.

Expert perspective on the poor outcomes observed with immunotherapy in NSCLC with STK11 or KEAP1 mutations, alone or in combination with KRAS alterations.

Insight on the outcomes seen with immunotherapy in non–small cell lung cancer with classical EGFR mutations or ALK rearrangements in the context of clinical study data.

The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer.

David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

The FDA has accepted for priority review a supplemental biologics license application for trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have a HER2 mutation and who have received a prior systemic therapy.

Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.

Meghan Mooradian, MD, highlights best practices for identifying molecular alterations in NSCLC and addresses barriers to testing.

Expert perspective on the current landscape of actionable mutations and molecular profiling in non–small cell lung cancer management.

New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.

The addition of adebrelimab to chemotherapy elicited improved overall survival compared with chemotherapy and placebo in patients with extensive-stage small cell lung cancer.

The addition of canakinumab to frontline pembrolizumab and chemotherapy did not improve survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer. However, signals of activity were seen in patients with a baseline inflammatory biomarker high sensitivity-C-reactive protein.